-
Start Preamble
ACTION:
Notice of application.
DATES:
Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before October 30, 2017.
ADDRESSES:
Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.
End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on July 6, 2017, Noramco, Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801-4417 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:
Controlled substance Drug code Schedule Marihuana 7360 I Tetrahydrocannabinols 7370 I Codeine-N-oxide 9053 I Dihydromorphine 9145 I Hydromorphinol 9301 I Start Printed Page 41056 Morphine-N-oxide 9307 I Amphetamine 1100 II Methylphenidate 1724 II Nabilone 7379 II Phenylacetone 8501 II Codeine 9050 II Dihydrocodeine 9120 II Oxycodone 9143 II Hydromorphone 9150 II Hydrocodone 9193 II Morphine 9300 II Oripavine 9330 II Thebaine 9333 II Opium extracts 9610 II Opium fluid extract 9620 II Opium tincture 9630 II Opium, powdered 9639 II Opium, granulated 9640 II Oxymorphone 9652 II Noroxymorphone 9668 II Tapentadol 9780 II The company plans to manufacture the above-listed controlled substances in bulk for distribution to its customers. In reference to drug code 7360, the company plans to manufacture a synthetic version of cannabidiol in bulk for sale to its customers, who are final dosage form manufacturers. No other activity for this drug code is authorized for this registration.
Start SignatureDated: August 21, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017-18315 Filed 8-28-17; 8:45 am]
BILLING CODE 4410-09-P
Document Information
- Published:
- 08/29/2017
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Action:
- Notice of application.
- Document Number:
- 2017-18315
- Dates:
- Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before October 30, 2017.
- Pages:
- 41055-41056 (2 pages)
- Docket Numbers:
- Docket No. DEA-392
- PDF File:
- 2017-18315.pdf